Erratum: Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study

Erratum: Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study

Saved in:

Bibliographic Details
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2023-07-01
Series:	Journal of Human Reproductive Sciences
Online Access:	https://journals.lww.com/10.4103/0974-1208.386502
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study
by: Nayana Hitesh Patel, et al.
Published: (2023-04-01)

Major results of a phase III comparative multicenter study on the follitropin alfa biosimilar (Primapur®) and the original follitropin alfa (Gonal-f®)
by: Z. B. Barakhoeva, et al.
Published: (2018-11-01)

An observational study «FOLLITROPIN» comparing the efficacy of follitropin alpha biosimilar: the real-world data
by: D. P. Kamilova, et al.
Published: (2021-03-01)

Pharmacoeconomic analysis of the application of follitropin alfa in combination with assisted reproductive technologies
by: K. A. Perova, et al.
Published: (2022-04-01)

Updated clinical and economic analysis of using follitropin alfa in combination with assisted reproductive technologies in 2022
by: D. G. Shchurov, et al.
Published: (2023-04-01)

Advisory Board on potential import substitution of follitropin alfa preparations in IVF cycles
by: article Editorial
Published: (2021-09-01)

THE NOVEL BIOSIMILAR OF FOLLITROPIN ALPHA TO BE MANUFACTURED IN RUSSIA STARTING FROM 2017
by: I. I. Vorobiev, et al.
Published: (2017-12-01)

Efficacy and safety of follitropin delta versus follitropin alpha/beta in infertility treatment: A systematic review and meta‐analysis
by: Shinnosuke Komiya, et al.
Published: (2024-01-01)

Real-world clinical outcomes of patients with CLN2 disease treated with cerliponase alfa
by: Angela Schulz, et al.
Published: (2025-03-01)

Comparative pharmacoeconomic analysis of follitropin delta application for superovulation induction during artificial insemination
by: I. S. Krysanov, et al.
Published: (2023-07-01)

A PEN INJECTOR FOR SELF-ADMINISTRATION OF FOLLITROPIN ALPHA SOLUTION WITH A MINIMAL DOSE INCREMENT OF 5 IU
by: A. B. Podkorytov, et al.
Published: (2018-02-01)

Estado vegetativo-alfa persistente
by: R. Oliveira-Souza, et al.
Published: (1989-06-01)

Efficacy and safety of сepeginterferon alfa-2b in double treatment regimen (cepeginterferon alfa-2b and ribavirin) of antiviral therapy in patients with chronic hepatitis C genotypes 2 and 3. Experience of real clinical practice
by: A. I. Pavlov, et al.
Published: (2016-11-01)

Real-world treatment with elosulfase alfa in patients with MPS IVA is associated with improved endurance over time
by: Barbara K. Burton, et al.
Published: (2025-01-01)

A real-world pharmacovigilance study of efgartigimod alfa in the FDA adverse event reporting system database
by: Yunlin Yang, et al.
Published: (2025-04-01)

Postmarketing adverse events of efgartigimod alfa: a real-world pharmacovigilance study based on the FAERS database
by: Yaxin Ju, et al.
Published: (2025-07-01)

Oglądając „Pannę Julię” Alfa Sjöberga
by: Tadeusz Szczepański
Published: (2002-12-01)

Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease
by: Barry J. Byrne, et al.
Published: (2024-10-01)

The efficacy and safety of double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alfa 2b and ribavirin) treatment regimens in chronic hepatitis C patients. The experience of everyday clinical practice
by: N. P. Blokhina, et al.
Published: (2016-07-01)

A Real-World Data Analysis of Alglucosidase Alfa in the FDA Adverse Event Reporting System (FAERS) Database
by: Yi Yin, et al.
Published: (2025-01-01)

Tailored therapy with turoctocog alfa pegol according to patient’s lifestyle and hemorrhagic phenotype: from clinical trial to real-life
by: Ilaria Nichele, et al.
Published: (2024-04-01)

Corrigendum: Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease
by: Barry J. Byrne, et al.
Published: (2025-01-01)

HISTÓRIA E MEMÓRIA: O PROGRAMA ALFA
by: Vânia Aparecida Martins Bernardes
Published: (2008-02-01)

Alfa-mannosidosis: Frequent Symptoms in Rare Patient
by: Nato D. Vashakmadze, et al.
Published: (2023-01-01)

DORNASE ALFA: WHAT EFFECTIVENESS OF MEDICATION DEPENDS ON?
by: O.I. Simonova
Published: (2009-07-01)

DETERMINATION OF DARBEPOETIN ALFA IN RABBIT PLASMA BY ELISA
by: M. V. Karlina, et al.
Published: (2019-01-01)

Estilos de vida da “Geração Alfa”
by: Paula Vianna Köche
Published: (2024-12-01)

Single-chain recombinant clotting factor VIII (lonoctocog alfa): clinical experience in Russia
by: M. V. Kosinova
Published: (2022-02-01)

Responses to peginterferon alfa-2a vs alfa-2b plus ribavirin in a Mexican population with chronic hepatitis C
by: Jorge Luis Sandoval-Ramirez, et al.
Published: (2015-03-01)

SPECIFIC DISORDERS OF THE RESPIRATORY SYSTEM IN CYSTIC FIBROSIS. CLINICAL EFFICACY OF THERAPY WITH DORNASE ALFA IN CHILDREN
by: T.V. Simanova, et al.
Published: (2010-11-01)

RECURRENT POLYSINUSITIS AS LEADING CLINICAL EVIDENCE OF CYSTIC FIBROSIS. SUCCESSFUL ENDONASAL APPLICATION OF DORNASE ALFA
by: I.K. Asherova, et al.
Published: (2009-10-01)

Real-world andexanet alfa utilization and the association between delay in administration due to hospital transfer and all-cause inpatient mortality
by: Huiqiao Fan, et al.
Published: (2025-01-01)

Epoetin Alfa: A Cause of Coronary Artery Thrombosis
by: Muhammad Umer Siddiqui, et al.
Published: (2017-01-01)

PET imaging of differentiated thyroid cancer with thyrotropin-alfa
by: Grayson R. Gimblet, et al.
Published: (2025-04-01)

P244: Clinical profiles of 134 patients with alpha-mannosidosis from the velmanase alfa clinical program and SPARKLE registry
by: Heather Morgan, et al.
Published: (2025-01-01)

Comparison of the efficacy and safety of the original rituximab and its biosimilar in routine clinical practice
by: D. A. Kusevich, et al.
Published: (2022-06-01)

Alfas, redpills e outras polêmicas tragicômicas no YouTube
by: Cristina Scheibe Wolff, et al.
Published: (2025-08-01)

165 An Analysis of the Use of Andexanet Alfa at the University of Utah Hospital
by: James R. Gustat, et al.
Published: (2025-05-01)

PECULIARITIES OF DORNASE ALFA AND KINESITHERAPY USE IN CHILDREN WITH CYSTIC FIBROSIS
by: O. I. Simonova
Published: (2013-07-01)

La enfermedad de Alzheimer: ¿Modelo de alfa-sinucleopatía?
by: Amilkar Suárez, et al.
Published: (2023-06-01)